baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out AYJ/ DE000SU9P1H1 /

20/09/2024 16:46:51	Chg.-0.110	Bid17:30:03	Ask-	Underlying	Strike price	Expiration date	Option type
0.430EUR	-20.37%	- Bid Size: -	- Ask Size: -	VALNEVA SE EO...	2.1409 -	31/12/2078	Call

GlobeNewswire 03/09 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...

GlobeNewswire 13/08 Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

GlobeNewswire 01/08 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’...

GlobeNewswire 22/07 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the Wo...

GlobeNewswire 17/07 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...

GlobeNewswire 01/07 Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ...

GlobeNewswire 26/06 Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...

GlobeNewswire 24/06 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

GlobeNewswire 05/06 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...

GlobeNewswire 04/06 Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

GlobeNewswire 03/06 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

GlobeNewswire 31/05 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

GlobeNewswire 21/05 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

GlobeNewswire 13/05 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...

GlobeNewswire 07/05 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire 26/03 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

GlobeNewswire 25/03 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

GlobeNewswire 21/03 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...

GlobeNewswire 20/03 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

GlobeNewswire 18/03 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...

GlobeNewswire 04/03 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

GlobeNewswire 29/02 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...

GlobeNewswire 15/02 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

GlobeNewswire 05/02 Valneva Announces Sale of Priority Review Voucher for $103 Million

GlobeNewswire 10/01 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

Soc. Generale Knock-Out AYJ/ DE000SU9P1H1 /

If you wish to receive reply to your feedback, please provide your email address.